Fluvoxamine treatment of obsessivecompulsive symptoms in schizophrenic patients: an add-on open study

Poyurovsky, Michael; Isakov, Victoria; Hromnikov, S; Modai, Ilan; Rauchberger, Boris; Schneidman, Michael; Weizman, Abraham

doi:10.1097/00004850-199903000-00006

Cited by 44 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,9 Aripiprazole has been used successfully to reduce OCS where SSRIs have failed. 14 In case 2 it has been shown that aripiprazole can be combined with an SSRI for difficult cases. Aripiprazole may also be useful in cases where it is unclear whether the new symptoms elicited are OCS or new psychotic symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…Aripiprazole may also be useful in cases where it is unclear whether the new symptoms elicited are OCS or new psychotic symptoms. 14 In previous papers, reducing the dose of clozapine has been considered as a strategy for reducing OCS. 2,3 This is in line with the evidence of positive correlation between clozapine dose and OCS.…”

Section: Discussionmentioning

confidence: 99%

“…13,14 It was also useful for reducing both negative and positive symptoms of schizophrenia. 15 Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

“…3,7 Some studies report an improvement when SSRIs are used. 13,14 We looked at three cases where an antipsychotic with high affinity for 5-HT 2a antagonism was used with the patient later developing new obsessive symptoms. Two of the patients were on clozapine and one was taking risperidone.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Obsessive‐compulsive symptoms: a side‐effect of antipsychotic treatment

Ukaegbu¹,

Dunne²,

Getachew³

2016

Prog Neurol Psychiatry

View full text Add to dashboard Cite

Obsessive‐compulsive symptoms (OCS) secondary to antiserotonergic antipsychotic treatment of schizophrenia appear to have a significant prevalence from previous studies but can be very difficult to detect as they are overshadowed by the diagnosis of schizophrenia. Here, the authors describe three cases where patients have developed OCS after starting risperidone in one case, and clozapine in two other cases and how significant improvements can be achieved with SSRIs and, if necessary, cognitive behavioural therapy (CBT).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Obsessive‐compulsive symptoms: a side‐effect of antipsychotic treatment

Ukaegbu¹,

Dunne²,

Getachew³

2016

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

“…However, before start of such a clinical test, careful considerations are required of the previous data indicating that SSRI augmentation of antipsychotics in the treatment of schizophrenia improved negative symptoms of schizophrenia and had no effect on positive symptoms (Silver and Shmugliakov, 1998;Silver, 2004), although the therapeutic target of the SSRIs is not the positive symptoms by themselves but the vulnerability to their relapse. It should also be noted that some cases were omitted from the clinical trials owing to the worsening of the positive symptoms (Silver and Shmugliakov, 1998;Poyurovsky et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors, Fluoxetine and Paroxetine, Attenuate the Expression of the Established Behavioral Sensitization Induced by Methamphetamine

Kaneko

Kashiwa

Ito

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

To obtain an insight into the development of a new pharmacotherapy that prevents the treatment-resistant relapse of psychostimulantinduced psychosis and schizophrenia, we have investigated in the mouse the effects of selective serotonin reuptake inhibitors (SSRI), fluoxetine (FLX) and paroxetine (PRX), on the established sensitization induced by methamphetamine (MAP), a model of the relapse of these psychoses, because the modifications of the brain serotonergic transmission have been reported to antagonize the sensitization phenomenon. In agreement with previous reports, repeated MAP treatment (1.0 mg/kg a day, subcutaneously (s.c.)) for 10 days induced a long-lasting enhancement of the increasing effects of a challenge dose of MAP (0.24 mg/kg, s.c.) on motor activity on day 12 or 29 of withdrawal. The daily injection of FLX (10 mg/kg, s.c.) or PRX (8 mg/kg, s.c.) from 12 to 16 days of withdrawal of repeated MAP administration markedly attenuated the ability of the MAP pretreatment to augment the motor responses to the challenge dose of the stimulant 13 days after the SSRI injection. The repeated treatment with FLX or PRX alone failed to affect the motor stimulation following the challenge of saline and MAP 13 days later. These results suggest that the intermittent and repetitive elevation of serotonergic tone may inhibit the expression of the motor sensitization induced by pretreatment with MAP. It is proposed that clinically available serotonin reuptake inhibitors could be useful for preventing the recurrence of hallucinatory-paranoid state in drug-induced psychosis and schizophrenia.

show abstract